Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease

Table 2 Baseline laboratory tests (prior to treatment)

Variables		Group A	Group B	p-value
Median (Min–Max)		Group A	Group B	p-value
WBC	(/μL)	12190.0 (6760.0–20640.0)	12890.0 (5080.0–30160.0)	N.S.
Neutrophil	(/μL)	7891.2 (4191.2–13130.1)	8659.0 (3518.1–26771.2)	N.S.
Hematocrit	(%)	33.2 (27.4–37.9)	31.7 (25.1–41.1)	N.S.
Platelet	(×104/μL)	36.3 (2.37–54.7)	38.6 (20.0–86.9)	N.S.
Total Bilirubin	(mg/dL)	0.7 (0.3–2.4)	0.6 (0.1–4.6)	N.S.
AST	(IU/L)	93.0 (22.0–290.0)	42.0 (20.0–648.0)	N.S.
ALT	(IU/L)	184.5 (14.0–364.0)	42.0 (7.0–606.0)	N.S.
Sodium	(mEq/L)	135.0 (130.0–139.0)	136.0 (130.0–143.0)	N.S.
CRP	(mg/dL)	8.8 (4.2–15.3)	7.4 (0.8–18.7)	N.S.
Albumin	(g/dL)	3.5 (2.8–3.8)	3.5 (2.5–4.3)	N.S.
D-dimer	(μg/mL)	1.9 (1.0–8.9)	1.3 (0.5–10.3)	N.S.
Fibrinogen	(mg/dL)	379.0 (550.0–875.0)	607.0 (392.0–901.0)	N.S.
ESR (60 min)	(mm)	100.5 (53.0–130.0)	99.0 (38.0–140.0)	N.S.

Note: Mann-Whitney test, N.S.: not significant.
WBC White blood cell, AST Aspartate aminotransferase, ALT Alanine aminotransferase.
CRP C-reactive protein, ESR Erythrocyte sedimentation rate.

ISSN: 1546-0096